Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02311907
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:17.411611+00:00
Published At
2017-02-23T00:00:00+00:00
Record Updated At
2017-02-23
Results Posted At
2017-02-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Chemotherapeutic Agent Toxicity", "Neuropathy", "Neurotoxicity Syndrome", "Pain", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIA Primary Peritoneal Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Primary Peritoneal Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Primary Peritoneal Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Cancer", "Stage IV Primary Peritoneal Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-02-23"
protocolSection.identificationModule.nctId
"NCT02311907"
protocolSection.identificationModule.officialTitle
"The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2017-02-23"

Study condition terms

  • Chemotherapeutic Agent Toxicity (protocolSection.conditionsModule.conditions)
  • Neuropathy (protocolSection.conditionsModule.conditions)
  • Neurotoxicity Syndrome (protocolSection.conditionsModule.conditions)
  • Pain (protocolSection.conditionsModule.conditions)
  • Stage IIIA Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIA Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIC Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Fallopian Tube Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Primary Peritoneal Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.